Get the Stockscreener App
331.17
5.84%
18.28
After Hours:
331.17
Insulet Corporation stock is traded at $331.17, with a volume of 1.42M.
It is up +5.84% in the last 24 hours and up +0.67% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$312.89
Open:
$321.965
24h Volume:
1.42M
Relative Volume:
2.29
Market Cap:
$23.30B
Revenue:
$2.36B
Net Income/Loss:
$236.10M
P/E Ratio:
100.78
EPS:
3.286
Net Cash Flow:
$382.50M
1W Performance:
-0.46%
1M Performance:
+0.67%
6M Performance:
+2.06%
1Y Performance:
+26.40%
1-Day Range:
$316.88
$334.47
1-Week Range:
$312.06
$354.88
52-Week Range:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
331.17 | 22.01B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Insulet Stock Prediction: Where Analysts See the Stock Going by 2027 - TIKR.com
Insulet drops on investor day as long-term outlook unveiled - MSN
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Finviz
Insulet Corporation (PODD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Canaccord Genuity raises Insulet stock price target to $432 on growth plan By Investing.com - Investing.com Nigeria
Canaccord Genuity raises Insulet stock price target to $432 on growth plan - Investing.com Nigeria
RBC Capital Maintains Insulet (PODD) Outperform Recommendation - Nasdaq
Insulet Corporation (PODD) PT Raised to $432 at Canaccord Genuity - StreetInsider
Insulet stock price target raised to $380 from $370 at BTIG - Investing.com Canada
Insulet stock holds Buy rating at UBS on strong growth outlook - Investing.com Nigeria
Truist Raises Price Target on Insulet to $412 From $390, Keeps Buy Rating - MarketScreener
RBC Raises Price Target on Insulet to $380 From $370, Keeps Outperform Rating - MarketScreener
Bernstein reiterates Outperform rating on Insulet stock with $410 target - Investing.com India
Bernstein reiterates Outperform rating on Insulet stock with $410 target By Investing.com - Investing.com UK
Bernstein on Insulet Corporation (PODD): 'We See Plenty of Upside Potential from Here' - StreetInsider
Insulet's (PODD) 'Competitive Moat Likely Underappreciated'UBS - StreetInsider
Truist Securities raises Insulet stock price target to $412 on growth outlook - Investing.com India
Insulet stock price target raised by Leerink Partners to $386 from $385 - Investing.com India
Raymond James raises Insulet stock price target on market leadership outlook - Investing.com Nigeria
Insulet Corporation stock hits all-time high at 354.0 USD By Investing.com - Investing.com Canada
BTIG Raises Target for Insulet (PODD) to $380, Maintains Buy Rat - GuruFocus
BTIG Adjusts Price Target on Insulet to $380 From $370, Maintains Buy Rating - MarketScreener
Raymond James Adjusts Price Target on Insulet to $385 From $366, Maintains Outperform Rating - MarketScreener
Leerink Partners Adjusts Price Target on Insulet to $386 From $385, Maintains Outperform Rating - MarketScreener
Insulet Corporation (PODD) PT Raised to $386 at Leerink Partners - StreetInsider
Insulet Corporation (PODD) PT Raised to $412 at Truist Securities - StreetInsider
Insulet Corporation (PODD) PT Raised to $380 at BTIG - StreetInsider
Insulet Corporation (PODD) PT Raised to $385 at Raymond James - StreetInsider
Is Insulet Corporation (GOV) stock at risk of policy regulationJuly 2025 Trade Ideas & Technical Entry and Exit Alerts - newser.com
Best data tools to analyze Insulet Corporation stock2025 Stock Rankings & Expert Approved Momentum Ideas - newser.com
Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap - MassDevice
Transcript : Insulet CorporationAnalyst/Investor Day - MarketScreener
Insulet (PODD) Shares Fall Amid Ambitious Growth Plans Unveiled - GuruFocus
Insulet targets 20% revenue growth, unveils next-gen diabetes tech By Investing.com - Investing.com Nigeria
Insulet projects revenue CAGR of 20% for 2025-2028 - MarketScreener
Insulet Projects Revenue CAGR Of 20% For 2025-2028 - TradingView
Insulet stock drops on investor day (PODD:NASDAQ) - Seeking Alpha
Insulet (PODD) Unveils Ambitious Growth Plans at Investor Day - GuruFocus
Insulet stock drops amid market weakness despite strong long-term outlook - Investing.com Nigeria
Insulet stock drops amid market weakness despite strong long-term outlook By Investing.com - Investing.com South Africa
Insulet targets 20% revenue growth, unveils next-gen diabetes tech - Investing.com
Insulet to launch next-gen Omnipod 6 in 2027, outlines plans for fully closed loop pump for type 2 - MassDevice
Insulet projects 20% revenue growth through 2028 at investor day - StreetInsider
Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day - Business Wire
Peering Into Insulet Corp's Recent Short Interest - Benzinga
Will Insulet Corporation (GOV) stock deliver compounding returnsJuly 2025 Summary & Daily Stock Trend Reports - newser.com
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):